Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Provider guidance is mandatory for dosing, monitoring, and side effect management
A phase 2 randomized, placebo-controlled interventional trial explored weight loss in patients with obesity or overweight with at least one weight-related coexisting condition was recently completed
For broader context on retatrutide's cardiovascular data across all trials, see our Cardiovascular Outcomes guide
Their benefits seem particularly pronounced in individuals with obesity, where weight reduction may amplify treatment response, positioning GLP-1based therapies as a promising option for selected patients
US$ 29.71
US$ 21.32
US$ 27.52
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820182.png)
US$ 27.54
US$ 25.47
US$ 26.25
US$ 27.41
US$ 22.85
US$ 28.04
